Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including Top 4 on ChinaVenture's 2025 China Best VC Firms List
The "ChinaVenture Ranking" has been published for 20 consecutive years, and is known throughout the industry for its professionalism, authority, and rigor. It is regarded as a bellwether for China's equity investment industry and serves as an important reference for capital commitments from many large institutional LPs.
ChinaVenture recently released its flagship China Venture Capital and Private Equity rankings — the "ChinaVenture Rankings." For 20 consecutive years, these rankings have been published by an independent third-party organization, earning a reputation within the industry for professionalism, authority, and rigor. They are widely regarded as a bellwether for China's equity investment sector and serve as a critical reference for major institutional LPs when making allocation decisions. Qiming Venture Partners and its portfolio companies received multiple honors in this year's rankings.
The annual rankings cover categories including Best Venture Capital Firm of the Year, Best Foreign Venture Capital Firm, Best Returning Venture Capital Firm, Best Industry Investor, and Best Industry Investment Case. In the firm rankings, Qiming Venture Partners was recognized with multiple awards.
Qiming Venture Partners
Received
Best Venture Capital Firm in China — Top 4
Best Foreign Venture Capital Firm in China — Top 2 Best Returning Venture Capital Firm in China — Top 10 Best Investor in Biopharma — Healthcare & Health Services Industry, China — Top 30 Best Investor in Medical Devices — Healthcare & Health Services Industry, China — Top 20 Best Investor in Healthcare Services — Healthcare & Health Services Industry, China — Top 10 Best Investor in Advanced Manufacturing — Advanced Manufacturing & High-Tech Industry, China — Top 30 Best Investor in AI & Big Data — AI & Big Data Industry, China — Top 30 Best Investor in Carbon Neutrality — Carbon Neutrality Industry, China — Top 30
In the company rankings, Qiming Venture Partners portfolio companies Kezhou Pharma, Shize Biotech, Syneron Bio, Zhitai Bio, Cornerstone Robotics, Nurotron, Tupu Medical, Huimei Technology, Insilico Medicine (03696.HK), Galaxy Universal, Yunji Technology (02670.HK), Pelliot, Insta360 (688775.SH), DeepWise, Shengshu Technology, Infinigence AI, Unisound (09678.HK), and Dishaang were named Best Industry Investment Cases.
Kezhou Pharma, Shize Biotech, Syneron Bio, Zhitai Bio
Named
Best Biopharma Investment Cases — Healthcare & Health Services Industry, China — Top 10
Cornerstone Robotics, Nurotron, Tupu Medical
Named
Best Medical Device Investment Cases — Healthcare & Health Services Industry, China — Top 10
Huimei Technology
Named
Best Healthcare Services Investment Cases — Healthcare & Health Services Industry, China — Top 5
Insilico Medicine
Named
Best Exit Cases — Healthcare & Health Services Industry, China — Top 5
Galaxy Universal
Named
Best Advanced Manufacturing Investment Cases — Advanced Manufacturing & High-Tech Industry, China — Top 10
Yunji Technology
Named
Best Advanced Manufacturing Exit Cases — Advanced Manufacturing & High-Tech Industry, China — Top 5
Pelliot
Named
Best Investment Cases — China's New Consumer Industry — Top 10
Insta360
Named
Best Exit Cases — China's New Consumer Industry — Top 3
DeepWise, Shengshu Technology, Infinigence AI
Named
Best AI & Big Data Investment Cases — AI & Big Data Industry, China — Top 10
Unisound
Named
Best AI & Big Data Exit Cases — AI & Big Data Industry, China — Top 3
Dishaang
Named
Best Investment Cases — China's Digitalization & Informatization Industry — Top 10
· 2025 ChinaVenture Rankings
Drawing on ChinaVenture Jiachuan CVSource data and surveys of over 1,000 active investment institutions in the private equity space, the ChinaVenture research team verified data against established selection criteria to identify outstanding firms.
The ChinaVenture research team found that 2025 did not bring a broad-based recovery to private equity investment. Instead, the industry saw deepening divergence. RMB funds continued to solidify their dominance, while USD funds experienced a structural resurgence. Capital became heavily concentrated in hard technology sectors, and exit pathways evolved from IPO dependence toward greater diversification.
As industry polarization intensifies and competitive dynamics and value propositions are reshaped, the ChinaVenture Rankings faithfully document the sector's evolutionary trajectory. Only institutions that identify their positioning and build durable competitive moats will establish themselves in this new cycle.
Source | ChinaVenture
Past Coverage
Qiming Headlines | Qiming Venture Partners and Portfolio Companies Honored with Multiple Awards in 2024 ChinaVenture Rankings, Including Best Venture Capital Firm in China — Top 5 Qiming Honors | Five Qiming Venture Partners Investors Named to 2025 ChinaVenture Investor Rankings Qiming Honors | Qiming Venture Partners and Investors Selected for Diyixinsheng 2025 China Investment Institutions and Individuals Rankings
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, among others.